{
  "docId": "019de077-58c2-77ec-8b05-6d27c4bb0498",
  "docSlug": "35a6e53e15f172ec3a7e4b1f473eaa42",
  "documentTitle": "Genprex | Investor Presentation Deck | 58 slides",
  "authorId": "genprex",
  "authorName": "Genprex",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 20,
  "pageCount": 58,
  "prevPage": 19,
  "nextPage": 21,
  "slideType": "traction",
  "function": "show_traction",
  "density": "balanced",
  "nDataPoints": 6,
  "notes": "The slide outlines a multi-phase clinical trial structure (Phase 1, 2a, 2b) and provides specific patient counts and interim analysis milestones.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-58c2-77ec-8b05-6d27c4bb0498/20",
  "deckHref": "/decks/019de077-58c2-77ec-8b05-6d27c4bb0498",
  "deckJsonHref": "/decks/019de077-58c2-77ec-8b05-6d27c4bb0498.json",
  "deckAnchorHref": "/decks/019de077-58c2-77ec-8b05-6d27c4bb0498#slide-20",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.98,
        "x": 0.01,
        "y": 0.575
      },
      "kind": "diagram",
      "text": "Phase 1, 2a, and 2b trial progression flow chart",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "df61e4d0-bfa0-4792-a225-43bad51569e0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.115,
        "x": 0.01,
        "y": 0.945
      },
      "kind": "image",
      "text": "Genprex logo",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5b9e488f-8ae1-4ea5-8804-525696d7f07d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.465,
        "x": 0.048,
        "y": 0.098
      },
      "kind": "paragraph",
      "text": "Patients with advanced, EGFR mutant NSCLC whose disease progressed after Tagrisso. FDA Fast Track Designation. ~10-15 U.S. sites. ~119 patients. Phase 1 Dose Escalation: 12 patients. Phase 2a Expansion: ~33 patients. Phase 2b: ~74 patients.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f39aa551-7220-48ad-b104-fc00e8ae9c08",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.075,
        "w": 0.275,
        "x": 0.641,
        "y": 0.125
      },
      "kind": "title",
      "text": "Acclaim-1",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "93e6ee69-5fe9-4d4a-bf91-69239e164e9d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "cc20ade6-56b7-4ccc-87a3-a3e28cfb083c",
      "evidence": "paragraph/paragraph: Patients with advanced, EGFR mutant NSCLC whose disease progressed after Tagrisso. FDA Fast Track Designation. ~10-15 U.S. sites. ~119 patients. Phase 1 Dose Escalation: 12 patients. Phase 2a Expansi",
      "confidence": 0.8
    }
  ],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "70465346-dca1-432c-9f99-3648d8089c94",
      "evidence": "The slide uses a sequential flow diagram to represent clinical trial phases.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 20,
      "from": 10,
      "beatId": "42876aa5-a597-4386-a7a4-77eba640e28a",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "Solution overview and clinical trial results",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 18,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "6f78c908-9d3e-4d22-b345-671df04f3614",
      "evidence": "Discussion of drug resistance and limited treatment options",
      "position": 0,
      "objective": "Highlight the consequences of not adopting Genprex's gene therapies",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}